GGrantIndex
Sort

25,944 grants matching neurodegeneration

FRIEDRIECHS ATAXIA, MITOCHONDRIA AND CELL DEATH

$225,624
University Of California Davis · R01 · FY2002 · AG

Molecular and Physiological Responses to Persistent Mitochondrial DNA Damage

$225,600
Joel Newman Meyer · Duke University · R21 · FY2009 · NS

Structure and Function of Neuronal Calcium Binding Proteins (CaBPs)

$225,527
James B Ames · University Of California At Davis · R01 · FY2009 · NS

Neuroimaging and Neuropathic Substrates of Cognitive Deficits in Mouse Models of HIV, METH and Aging

$225,304
Svetlana Semenova · University Of California, San Diego · P50 · FY2015 · DA

CATECHOL THIOETHERS IN PARKINSON'S DISEASE

$225,177
Vanderbilt University · R01 · FY2001 · ES

Saracatinib Mitigates OP nerve agent-induced Long-term Neurotoxicity

$225,140
Thimmasettappa Thippeswamy · Iowa State University · R21 · FY2019 · NS

Towards GLIMPSE: Enabling technology to map cytokines in inflamed tissue

$225,135
Rebecca R Pompano · University Of Virginia · R21 · FY2021 · AI

CRCNS: The diffusional complexity of the brain's extracellular space

$225,097
Fidel Santamaria · University Of Texas San Antonio · R01 · FY2022 · NS

Role of EAAT2 and AEG-1 in Astrocyte Dysfunction and Neurodegeneration

$225,083
Paul B Fisher · St. Luke'S-Roosevelt Inst For Hlth Scis · P01 · FY2006 · NS

HIV Effects on Astrocyte Function and Astrocyte-Neuronal Interactions

$225,083
David J Volsky · St. Luke'S-Roosevelt Inst For Hlth Scis · P01 · FY2006 · NS

The role of mito-nuclear communication in the adaptation to mitochondrial dysfunction and stress resistance

$225,082
Alaattin Kaya · Virginia Commonwealth University · R35 · FY2024 · GM

TAU ALTERATIONS IN ALZHEIMER'S AND RELATED DEMENTIAS

$225,010
Massachusetts General Hospital · P50 · FY2005 · AG

Parkin and MGRN1: common roles in mitochondria and neurodegeneration?

$225,000
Teresa M Gunn · Mc Laughlin Research Institute · R21 · FY2010 · NS

SBIR Phase I: Engaging the Mind and Body: Technology to Automate Physical Therapy Treatments for Patients with Parkinson's Disease (PD).

$225,000
Bennett Gatto · Active Therapy Systems Llc · · FY2018 · TIP

Development of a kit for characterization of cellular energetics in single cells in cell and tissue cultures based on the measurement of the absolute magnitude of the mitochondrial membrane potential

$225,000
Akos A Gerencser · Image Analyst Software · R41 · FY2016 · DA

UBIQUITINATED PROTEIN DEGRADATION &NEURODEGENERATION

$225,000
Hunter College · R01 · FY2002 · NS

UBIQUITINATED PROTEIN DEGRADATION &NEURODEGENERATION

$225,000
Hunter College · R01 · FY2000 · NS

UBIQUITINATED PROTEIN DEGRADATION &NEURODEGENERATION

$225,000
Hunter College · R01 · FY2001 · NS

Extracellular alpha-synuclein in Parkinson's Disease

$225,000
Pamela J McLean · Mayo Clinic Jacksonville · R01 · FY2011 · NS

Tat and CDK9 on gene expression alterations coupled to HIV-1 Associated Dementia

$225,000
Xavier Grana · Temple Univ Of The Commonwealth · R21 · FY2009 · MH

Axonal Transport HTS Platform for Neurodegeneration Drug Discovery

$225,000
Robert G Lowery · Bellbrook Labs, Llc · R41 · FY2015 · NS

Enzyme Replacement Therapy for GM1 Gangliosidosis Lysosomal Rare Disease

$225,000
David Radin · Biostrategies, Lc · R43 · FY2014 · NS

Human Neural Stem Cells for HD: Technical and Empirical Advances

$225,000
Jeffrey H Kordower · Rush University Medical Center · R21 · FY2012 · NS

New Targeted BDNF Nanoparticles for Treatment of Dopaminergic Neurodegeneration in METH Addiction and HAND

$225,000
Franco Vitaliano · Exqor Technologies, Inc. · R43 · FY2017 · DA

IND, FIH study and 3-month tox for PTI-125, a novel therapeutic for Alzheimer's disease

$225,000
Lindsay H Burns · Cassava Sciences, Inc · R44 · FY2017 · AG